In Russia there are some restrictions that complicate the care of patients with malignant blood diseases, and currently the situation is aggravated by the spread of coronavirus infection. Current problems of diagnosis and treatment of patients with acute myeloid leukemia (AML) were discussed at the conference “Current issues of AML: barriers and possibilities of modern therapy.”
In his speech, chief specialist-hematologist of the health Committee of Volgograd region Administration, head of the Department of Hematology of the INSTITUTION “Volgograd regional clinical Oncology dispensary” Kamil Kaplanov Daniyalovich said that the pandemic COVID-19 and associated challenges had a negative impact on the regional blood centers. “There are certain nuances of providing blood components during a pandemic coronavirus infection, as it affects the work of the regional blood center,” said Kaplanov. He stressed that the outbreak of the coronavirus will not affect the diagnosis of AML.
Among other problems in providing medical care to patients with AML not associated with COVID-19, the kaplans described the cytarabine shortage, limited availability of new drugs (midostaurin and venetoklis), as well as the need for PCR and cytogenetic research at the expense of patients, as these types of studies are not included in the program of the MLA.
Parovichnikova Elena Nikolaevna, head of Department of chemotherapy of hematological malignancies, depression of hematopoiesis and bone marrow transplantation fgbu “SMRC Hematology” Ministry of health of Russia, in turn, noted the complexity of registration of cases of AML. “There is a register of cancer patients in the country, but there registration is an outdated method. We know that acute myeloid leukemia are registered there, they are kept for several positions, but competent, clear, modern, registration, AML does not exist. We have very good local registers, as, for example, in the Volgograd region, but around the country, unfortunately, the situation does not meet modern standards. Cases are recorded, but not adequately,” – said Parovichnikova.
The expert also noted the inability to include all patients into appropriate clinical trials. According to her, in some foreign countries, almost all patients with AML under 60 years were included in clinical studies, thus enhancing their survival. “Clinical research is strict adherence to all policies and procedures of treatment. For several years we in Russia tried to cooperate and not sponsored by pharmaceutical companies organize clinical studies. This Association of doctors-enthusiasts who are conducting research through public funds, which manage to attract. Only in the context of these studies fails to increase survival in patients with AML younger than 60 years from 25% to 38-45%. We hoped that in the near future we will be able to cross the 50% line”, – she told.